Business
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
First blood-only liquid biopsy test for minimal residual disease now covered for patients with stage II or III colorectal cancer Test used after surgery or
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nFirst blood-only liquid biopsy test for minimal residual disease now covered for patients with stage II or III colorectal cancer\n\n\n\nTest used after surgery or curative treatment to inform physician decisions about adjuvant therapy and to monitor for disease progression, recurrence or relapse\n\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is the first blood-only liquid biopsy test commercially available for MRD testing.\n\n\nGeisinger is providing coverage for the Guardant Reveal test for individuals with stage II or III colorectal cancer after curative treatment (including surgery) to inform physician decisions about post-treatment therapy and to monitor for disease progression, recurrence or relapse. The frequency of testing covered is aligned with monitoring guidelines established by the National Comprehensive Cancer Network for colorectal cancer. It includes the initial ctDNA test 4 to 6 weeks after surgery (or 2 to 4 weeks after completion of systemic therapy) and thereafter every 3 to 6 months for the first two years, and every 6 to 12 months for the following 3 years.\n\n\n“We are pleased that Geisinger Health Plan has taken this important step to make blood testing for residual disease more accessible to its members,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “This decision will help oncologists make more informed decisions about treatment and monitoring for colorectal cancer patients and survivors, to help improve their outcomes.”\n\n\nMinimal residual disease refers to a subclinical measure of cancer burden that remains during and following treatment. A patient’s MRD status is a reliable indicator of clinical outcome and response to therapy and can be used for risk stratification and to guide treatment options when used in conjunction with other clinical data.\n\n\nThe Geisinger Health Plan provides coverage for more than half a million members....